Status:
COMPLETED
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
Lead Sponsor:
Avid Radiopharmaceuticals
Conditions:
Alzheimer's Disease
Mild Cognitive Impairment
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 mo...
Detailed Description
Study AV-45-A11 is designed to determine if brain amyloid aggregation imaged on 18F-AV-45 PET scans is predictive of progression of cognitive impairment during the subsequent 36 months. Approximately ...
Eligibility Criteria
Inclusion
- All subjects who enrolled in study AV-45-A05(NCT00702143), received 18F-AV-45, and completed a PET scan will be eligible to enroll in this trial.
Exclusion
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
152 Patients enrolled
Trial Details
Trial ID
NCT00857506
Start Date
January 1 2009
End Date
December 1 2011
Last Update
March 28 2013
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85258
2
Research Site
Tucson, Arizona, United States, 85741
3
Research Site
Costa Mesa, California, United States, 92626
4
Research Site
Brooksville, Florida, United States, 34613